Vertex Pharma Reports Positive Phase 2 Data With VX-150 Proof-of-Concept Study

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) reported positive results of a Phase 2 study of the investigational NaV1.8 inhibitor VX-150 in patients with pain caused by small fiber neuropathy. The company said the study met its primary endpoint and showed that treatment with VX-150 demonstrated statistically significant and clinically meaningful pain reduction at Week 6. VX-150 was generally well tolerated in this study.

Jeffrey Leiden, CEO of Vertex, said: "These results show a potential path for the treatment of pain at a time when there is great clinical and societal need for new medicines. We continue to progress VX-150 toward pivotal development and also plan to advance additional NaV1.8 pain medicines into clinical development beginning in 2019."